Adenovirus (Ad) ocular infections (epidemic keratoconjunctivitis [EKC], follicular conjunctivitis, and pharyngeal conjunctival fever) are the most common ocular viral infections worldwide. At present there is no FDA approved antiviral for the treatment of these infections. A novel approach to antiviral development is the use of ribonucleases, which are enzymes that degrade RNA. OKG-0301 is a novel ribonuclease that can enter host cells and preferentially degrade viral tRNA leading to an inhibition of protein synthesis. It has been previously shown to have antiviral activity against HIV2.